Model Medicines GALILEO platform leverages GenAI to accelerate drug discovery, achieving rapid identification of novel antiviral compounds.

Model Medicines has introduced GALILEO, a GenAI platform designed to optimize the creation of non-viral medicines and improve drug discovery efficiency. This platform leverages AI technology to overcome traditional challenges in material design and research. Traditional drug discovery is slow and resource-intensive, but GALILEO overcomes these challenges by generating and analyzing a solution space of 50 trillion compounds. Using a multimodal, one-shot approach, the platform identified 12 new chemical entities (NCEs) with broad-spectrum antiviral activity against Hepatitis C and coronaviruses. This AI-driven process dramatically reduces time and costs compared to conventional methods.

GALILEO integrates bioinformatics, chemistry, and AI to design precise molecular structures, engineering in potency while eliminating off-target effects. The model fine-tunes drug properties, ensuring higher specificity—up to 15,000 times greater than previous compounds. By continuously expanding its chemical library, Model Medicines is refining next-generation antivirals and advancing new treatments for oncology and rare diseases.

With IND-enabling studies underway, the company plans to advance these NCEs into preclinical trials. It is also exploring partnerships to extend GALILEO’s applications, aiming to revolutionize drug development beyond antivirals. The platform’s ability to generate novel, high-efficacy compounds marks a significant leap in AI-driven pharmaceutical research. Model Medicines is advancing its initiatives further by launching the Model Medicines Endeavor program. This program aims to develop targeted spin-outs like VIROMME, focusing on infectious diseases. By leveraging GenAI and its library of NCEs, VIROMME seeks to create life-saving antivirals. The integration of GenAI within GALILEO not only opens new avenues for drug discovery but also positions Model Medicines as a leader in utilizing AI for transformative healthcare solutions.